Incremental cost of non-invasive prenatal diagnosis versus invasive prenatal diagnosis of fetal sex in England

Prenatal Diagnosis

Volumn 31, Issue 3, 2011, Pages 267-273

  Hill, Melissa ^a,b   Taffinder, Sally ^a,c   Chitty, Lyn S ^a,b   Morris, Stephen ^a,d  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b Clinical Molecular Genetics   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cost; Fetal sex determination; Non invasive prenatal diagnosis

Indexed keywords

DNA;

AMBIGUOUS GENITALIA; ARTICLE; CELL FREE SYSTEM; CHORION VILLUS SAMPLING; COMPARATIVE EFFECTIVENESS; CONGENITAL ADRENAL HYPERPLASIA; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DOWN SYNDROME; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; FETUS ECHOGRAPHY; FETUS KARYOTYPING; HUMAN; INTERMETHOD COMPARISON; INVASIVE PROCEDURE; LABORATORY TEST; MAJOR CLINICAL STUDY; NON INVASIVE MEASUREMENT; PATIENT COUNSELING; POLYMERASE CHAIN REACTION; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROBABILITY; RISK BENEFIT ANALYSIS; SEX DETERMINATION; SPONTANEOUS ABORTION; TISSUE CULTURE; UNITED KINGDOM;

ADRENAL HYPERPLASIA, CONGENITAL; BLOOD CHEMICAL ANALYSIS; COSTS AND COST ANALYSIS; DNA; ENGLAND; FEMALE; FETUS; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; SEX DETERMINATION ANALYSIS;

EID: 79952230961     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2680     Document Type: Article

References (29)

1. Birch L, English CA, O'donoghue K, Barigye O, Fisk NM, Keer JT. 2005. Accurate and robust quantification of circulating fetal and total DNA in maternal plasma from 5 to 41 weeks of gestation. Clin Chem 51: 312-320.
2. British National Formulary. 2010. [Accessed on 01 May 2010].
3. Bustamante-Aragones A, Rodriguez De Alba M, Gonzalez-Gonzalez C, et al. 2008. Foetal sex determination in maternal blood from the seventh week of gestation and its role in diagnosing haemophilia in the foetuses of female carriers. Haemophilia 14: 593-598.
4. Carroll AE, Downs SM. 2006. Comprehensive cost-utility analysis of newborn screening strategies. Pediatrics 117: S287-S295.
5. Costa JM, Benachi A, Gautier E, Jouannic JM, Ernault P, Dumez Y. 2001. First-trimester fetal sex determination in maternal serum using real-time PCR. Prenat Diagn 21: 1070-1074.
6. Cremonesi L, Galbiati S, Foglieni B, et al. 2004. Feasibility study for a microchip-based approach for noninvasive prenatal diagnosis of genetic diseases. Ann N Y Acad Sci 1022: 105-112.
7. Curtis L. 2009. Unit costs of health and social care. PSSRU. [Accessed on 01 June 2010].
8. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. 2002. Survival in Duchenne muscular dystrophy: Improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 12: 926-929.
9. Efrat Z, Akinfenwa OO, Nicolaides KH. 1999. First-trimester determination of fetal gender by ultrasound. Ultrasound Obstet Gynecol 13: 305-307.
10. Efrat Z, Perri T, Ramati E, Tugendreich D, Meizner I. 2006. Fetal gender assignment by first-trimester ultrasound. Ultrasound Obstet Gynecol 27: 619-621.
11. Emerson DS, Felker RE, Brown DL. 1989. The sagittal sign. An early second trimester sonographic indicator of fetal gender. J Ultrasound Med 8: 293-297.
12. Finning KM, Chitty LS. 2008. Non-invasive fetal sex determination: impact on clinical practice. Semin Fetal Neonatal Med 13: 69-75.
13. Firth HV, Boyd PA, Chamberlain Pf, Mackenzie Iz, Morriss-Kay Gm, Huson Sm. 1994. Analysis of limb reduction defects in babies exposed to chorionic villus sampling. Lancet 343: 1069-1071.
14. Forest M, Morel Y, David M. 1998. Prenatal treatment of congenital adrenal hyperplasia. Trends Endocrinol Metab 9: 284-289.
15. Harris RA, Washington AE, Nease RF Jr., Kuppermann M. 2004. Cost utility of prenatal diagnosis and the risk-based threshold. Lancet 363: 276-282.
16. Hill M, Finning K, Martin P, et al. 2010. Non-invasive prenatal determination of fetal sex: translating research into clinical practice. Clin Genet. [Epub ahead of print]. DOI: 10.1111/j.1399-0004.2010.01533.x.
17. Hyett JA, Gardener G, Stojilkovic-Mikic T, et al. 2005. Reduction in diagnostic and therapeutic interventions by non-invasive determination of fetal sex in early pregnancy. Prenat Diagn 25: 1111-1116.
18. Lajic S, Wedell A, Bui T, Ritzén E, Holst M. 1998. Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 83: 3872-3880.
19. Lo YM, Tein MS, Lau TK, et al. 1998. Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal diagnosis. Am J Hum Genet 62: 768-775.
20. Mangham LJ, Petrou S, Doyle LW, Draper ES, Marlow N. 2009. The cost of preterm birth throughout childhood in England and Wales. Pediatrics 123: e312-e327.
21. Mazza V, Contu G, Falcinelli C, et al. 1999. Biometrical threshold of biparietal diameter for certain fetal sex assignment by ultrasound. Ultrasound Obstet Gynecol 13: 308-311.
22. Mielke G, Kiesel L, Backsch C, Erz W, Gonser M. 1998. Fetal sex determination by high resolution ultrasound in early pregnancy. Eur J Ultrasound 7: 109-114.
23. Mujezinovic F, Alfirevic Z. 2007. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol 110: 687-694.
24. Odeh M, Grinin V, Kais M, Ophir E, Bornstein J. 2009. Sonographic fetal sex determination. Obstet Gynecol Surv 64: 50-57.
25. Ouyang L, Grosse SD, Kenneson A. 2008. Health care utilization and expenditures for children and young adults with muscular dystrophy in a privately insured population. J Child Neurol 23: 883-888.
26. Ritchie K, Bradbury I, Slattery J, Wright D, Iqbal K, Penney G. 2005. Economic modelling of antenatal screening and ultrasound scanning programmes for identification of fetal abnormalities. BJOG 112: 866-874.
27. Scheffer PG, Van Der Schoot CE, Page-Christiaens GC, Bossers B, Van Erp F, De Haas M. 2010. Reliability of fetal sex determination using maternal plasma. Obstet Gynecol 115: 117-126.
28. Torrance N, Mollison J, Wordsworth S, et al. 2006. Genetic nurse counsellors can be an acceptable and cost-effective alternative to clinical geneticists for breast cancer risk genetic counselling. Evidence from two parallel randomised controlled equivalence trials. Br J Cancer 95: 435-444.
29. Whitlow BJ, Lazanakis MS, Economides DL. 1999. The sonographic identification of fetal gender from 11 to 14 weeks of gestation. Ultrasound Obstet Gynecol 13: 301-304.